Projekt

A key promise of personalized medicine is that once realised, all citizens - irrespective of whether they are in cities or in rural areas - will be able to equally benefit from state-of-the-art individualized health care. The project will employ a transdisciplinary approach driven by AI to democratize precision medicine for prostate cancer in a regionally oriented model project targeting 8% of the German population, which in the future may be expanded inter-regionally or internationally. This will build on machine learning methods, to guide targeted treatment decisions based on deep learning classifiers that integrate longitudinally observed clinical measurements with multi-omic data. Altogether, the project represents a step towards the sharing of human, physical, and intellectual resources in healthcare consistent with social values and individuals' reasonable expectations and the concepts of fairness, inclusivity and equality. It will additionally foster the further development of AI as a technological framework for public health governance and enable enhanced standardization of the implementation of the human right to health.

• Prof. Dr. Oliver Stegle, Ph.D.

  Deutsches Krebsforschungszentrum
  Heidelberg
  Computational Genomics and Systems Genetics
  Heidelberg
  

• Prof. Dr. Thorsten Schlomm

  Charité - Universitätsmedizin Berlin
  Klinik für Urologie
  Berlin
  

• Dr. Jan Korbel, Ph.D.

  EMBL Europäisches Laboratorium
  für Molekularbiologie
  Genome Biology Unit
  Heidelberg
  

• Prof. Dr. Fruzsina Molnár-Gabór

  Universität Heidelberg
  Juristische Fakultät
  BioQuant-Zentrum (BQ 049)
  Heidelberg
  

• Herausforderungen an die haftungsrechtlichen Bestimmungen von KI

• Juristische Aspekte